IP Library Granted Patent US 12692545
Granted Patent B2
US 12692545 · App. 17/298,299 · Granted Jul 28, 2026

Combined auxiliary diagnostic method, kit, system and use of point mutation and methylation of bladder cancer driver genes

Inventors: Li Lu (Hunan, CN); Genming Xu (Hunan, CN); Qian Zhao (Hunan, CN)
C12Q1/6886C12Q2600/154C12Q2600/156
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12692545
App. No.
17/298,299
Granted
Jul 28, 2026
Kind
B2
Abstract

Disclosed are the method, kit, system and use for screening or detecting or assisting in the diagnosis of bladder cancer, which are able to simultaneously detect FGFR3, TERT, PLEKHS1 point mutations and OTX1, NID2 and NRN1 methylation levels, thereby realizing the combined detection of gene point mutation and methylation, reducing the demand for samples, experimental operation steps and detection cycle, and improving the specificity and sensitivity of detection.

Claims (88)

1 . A detection reagent for screening bladder cancer by targeting driver genes related to the pathway of bladder cancer, comprising specific primers and probes designed for detection of regions in a template, wherein the regions to be detected comprise at least one of a gene point mutation or a gene methylation;

wherein the gene point mutation comprises a FGFR3 point mutation, a TERT point mutation, and a PLEKHS1 point mutation,

wherein the gene methylation comprises OTX1 methylation, NID2 methylation, and NRN1 methylation,

wherein the region to be detected for the FGFR3 point mutation is the sequence set forth in SEQ ID NO: 1; the region to be detected for the TERT point mutation is the sequence set forth in SEQ ID NO: 2; and the region to be detected for the PLEKHS1 point mutation is the sequence set forth in SEQ ID NO: 3, wherein no transformation or sequence alteration of the gene point mutation sequences is required;

wherein the region to be detected for the OTX1 methylation is the sequence set forth in SEQ ID NO: 4; the region to be detected for the NID2 methylation is the sequence set forth in SEQ ID NO: 5; and the region to be detected for the NRNI methylation is the sequence set forth in SEQ ID NO: 6;

wherein the specific primers and probes designed for the regions to be detected in the template are the following primer pairs and probes:

the forward primer, reverse primer, and probe for the FGFR3 point mutation are the sequences set forth in SEQ ID NOs: 10, 11 and 12 respectively;

the forward primer, reverse primer, and probe for the TERT point mutation are the sequences set forth in SEQ ID NOs: 16, 17 and 18 respectively;

the forward primer, reverse primer, and probe for the PLEKHS1 point mutation are the sequences set forth in SEQ ID NOs: 22, 23 and 24 respectively;

the forward primer, reverse primer, and probe for the OTX1 methylation are the sequences set forth in SEQ ID NOs: 25, 29 and 30 respectively;

the forward primer, reverse primer, and probe for the NID2 methylation are the sequences set forth in SEQ ID NOs: 31, 34 and 35 respectively;

the forward primer, reverse primer, and probe for the NRN1 methylation are the sequences set forth in SEQ ID NOs: 36, 38 and 37 respectively;

wherein the detection reagent further comprises primers and a probe designed for an internal reference gene, wherein the internal reference gene is ATCB; and

wherein the primers and probe designed for the internal reference gene are the sequences set forth in SEQ ID NOs: 41-43.

2 . The detection reagent according to claim 1 , wherein the specific primers and probes for detecting the gene point mutation and/or gene methylation are further distributed in different reaction tubes, the reaction tubes are respectively a reaction tube A and a reaction tube B,

wherein the reaction tube A is used to detect the gene point mutation point mutations, and a composition thereof is as follows:

Reagent Name

Reaction Volume (μL)

Primer&Probe A

2

2× Gold 360 Master Mix

25

PCR enhancer

1

nucleic acid to be detected

5

NF-H 2 O

17

total volume

50

wherein, Primer&Probe A is a mixture composed of the primer pairs and probes for detection of the point mutations in FGFR3\TERT\PLEKHS1 and the internal reference gene primers and probe; and

wherein the reaction tube B is used to detect gene methylation, and the composition thereof is as follows:

Reagent Name

Reaction Volume (μL)

Primer&Probe B

2

2× Gold 360 Master Mix

25

PCR enhancer

1

purified nucleic acid after heavy salt

5

transformation

NF-H 2 O

17

total volume

50

wherein, Primer&ProbeB is a mixture composed of the primer pairs and probes for detection of methylation in OTX1\NRN1\NID2 and internal reference gene primers and probes.

3 . The detection reagent according to claim 1 , comprising the following components:

Reagent Name

Effective Components

Primer&Probe A

A mixture of primer pairs and probes for

detection of the point mutations in FGFR3.

TERT, and PLEKHS1 and the internal

reference gene

Primer&Probe B

A mixture of primer pairs and probes for

detection of methylation in OTX1, NRN1,

and NID2 and the internal reference gene

DNA polymerase

DNA polymerase, dNTPs, Mg 2+ , Tris-HCl,

Master Mix

NaCl and nuclease-free water

PCR enhancer

DTT and/or BSA

point mutation positive

adenovirus packaging positive mutant

quality control

plasmid

methylation positive

methylation-positive nucleic acid after

quality control

methylase transformation

negative control

T cells after wild-type plasmid transfection

NF-H 2 O

nuclease-free water

wherein the sequences and concentration of each primer pair and probe in Primer&Probe A are as follows:

the forward primer, reverse primer and probe for the FGFR3 point mutation are the sequences set forth in SEQ ID NOs: 10, 11 and 12, and the concentrations are 25 μM, 25 μM and 15 μM respectively;

the forward primer, reverse primer and probe for the TERT point mutation are the sequences set forth in SEQ ID NOs: 16, 17 and 18, and the concentrations are 25 μM, 25 μM and 10 μM respectively;

the forward primer, reverse primer and probe for the PLEKHSI point mutation are the sequences set forth in SEQ ID NOs: 22, 23 and 24, and the concentrations are 25 μM, 25 μM and 8 μM respectively; and

the forward primer, reverse primer and probe for the internal reference gene are the sequences set forth in SEQ ID NOs: 41-43 and the concentrations are 2.5 μM, 2.5μM and 5 μM respectively; and

wherein the sequences and concentration of each primer pair and probe in Primer&Probe B are as follows:

the forward primer, reverse primer and probe for the OTX1 methylation are the sequences set forth in SEQ ID NOs: 25, 29 and 30, and the concentrations are 25 μM, 25 μM and 15 μM respectively;

the forward primer, reverse primer and probe for the NID2 methylation are the sequences set forth in SEQ ID NOs: 31, 34 and 35, and the concentrations are 25 μM, 25 μM and 15 μM respectively;

the forward primer, reverse primer and probe for the NRN1 methylation are the sequences set forth in SEQ ID NOs: 36, 38 and 37, and the concentrations are 25 μM, 25μM and 15 μM respectively; and

the forward primer, reverse primer and probe for the internal reference gene are the sequences set forth in SEQ ID NOs: 41-43, and the concentrations are 2.5 μM, 2.5 μM and 5 μM, respectively.